Principal Investigator
Warren Alperstein
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250524
Clinical Trial Summary
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
Phase
Phase II
Funding Agency/Sponsor
National Cooperative Group
Disease
Pediatric Cancer
Contact Information
Phone Number
305-243-2647